NEW YORK — Quanterix said on Monday it has inked a non-exclusive agreement with Brigham and Women's Hospital for a SARS-CoV-2 serology test on its Simoa multiplex immunoassay platform.
The agreement enables Quanterix to use the technology to conduct serological assay to address unmet needs in the clinical setting, in epidemiological studies, and for therapeutic and vaccine development.